TY - JOUR
T1 - Risk factors for extended-spectrum-β-lactamaseproducing Escherichia coli in community-onset bloodstream infection
T2 - Impact on long-term care hospitals in Korea
AU - Baek, Yae Jee
AU - Kim, Young Ah
AU - Kim, Dokyun
AU - Shin, Jong Hee
AU - Uh, Young
AU - Shin, Kyeong Seob
AU - Shin, Jeong Hwan
AU - Jeong, Seok Hoon
AU - Lee, Geun Woo
AU - Lee, Eun Ji
AU - Kim, Dong Sook
AU - Park, Yoon Soo
N1 - Funding Information:
The study was supported by the research programs funded by the Korea Centers for Disease Control & Prevention (2017E280-401#, PI: YSP; 2017E4400100#, PI: SHJ).
Publisher Copyright:
© Korean Society for Laboratory Medicine
PY - 2021/9
Y1 - 2021/9
N2 - Background: The prevalence of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in the community has increased worldwide due to multifactorial reasons. ESBL-EC bloodstream infection (BSI) complicates the decision for proper antimicrobial administration. In this multicenter study, we investigated the prevalence, risk factors, and molecular background of community-onset (CO) ESBL-EC BSI. Methods: We included data for all episodes of ESBL-EC BSI of community origin from May 2016 to April 2017 obtained from the Korean national antimicrobial resistance surveillance system, which comprises six sentinel hospitals. Data, including previous history of admission and use of antimicrobials and medical devices before BSI, were collected, along with microbiological analysis results. Results: Among 1,189 patients with CO BSI caused by E. coli, 316 (27%) were identified as ESBL producers. History of admission, especially to a long-term care hospital (LTCH), and previous use of β-lactams/β-lactamase inhibitors, carbapenem, lincosamide, aminoglycoside, and extended-spectrum cephalosporin were independent risk factors for CO ESBL-EC BSI; admission to an LTCH showed the highest odds ratio (3.8, 95% confidence interval 2.3-6.1). The most common genotype was CTX-M-15 (N=131, 41%), followed by CTX-M-14 (N=86, 27%). ST131 was the most common sequence type among ESBL-EC groups (57%). Conclusions: In Korea, 27% of CO E. coli BSI were caused by ESBL producers. From perspectives of empirical treatment and infection control, history of admission to an LTCH and antimicrobial use should be noted.
AB - Background: The prevalence of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in the community has increased worldwide due to multifactorial reasons. ESBL-EC bloodstream infection (BSI) complicates the decision for proper antimicrobial administration. In this multicenter study, we investigated the prevalence, risk factors, and molecular background of community-onset (CO) ESBL-EC BSI. Methods: We included data for all episodes of ESBL-EC BSI of community origin from May 2016 to April 2017 obtained from the Korean national antimicrobial resistance surveillance system, which comprises six sentinel hospitals. Data, including previous history of admission and use of antimicrobials and medical devices before BSI, were collected, along with microbiological analysis results. Results: Among 1,189 patients with CO BSI caused by E. coli, 316 (27%) were identified as ESBL producers. History of admission, especially to a long-term care hospital (LTCH), and previous use of β-lactams/β-lactamase inhibitors, carbapenem, lincosamide, aminoglycoside, and extended-spectrum cephalosporin were independent risk factors for CO ESBL-EC BSI; admission to an LTCH showed the highest odds ratio (3.8, 95% confidence interval 2.3-6.1). The most common genotype was CTX-M-15 (N=131, 41%), followed by CTX-M-14 (N=86, 27%). ST131 was the most common sequence type among ESBL-EC groups (57%). Conclusions: In Korea, 27% of CO E. coli BSI were caused by ESBL producers. From perspectives of empirical treatment and infection control, history of admission to an LTCH and antimicrobial use should be noted.
UR - http://www.scopus.com/inward/record.url?scp=85104099999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104099999&partnerID=8YFLogxK
U2 - 10.3343/ALM.2021.41.5.455
DO - 10.3343/ALM.2021.41.5.455
M3 - Article
C2 - 33824233
AN - SCOPUS:85104099999
SN - 2234-3806
VL - 41
SP - 455
EP - 462
JO - Annals of Laboratory Medicine
JF - Annals of Laboratory Medicine
IS - 5
ER -